Related Pages for DRREDDY
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
DRREDDY
Related News - DRREDDY
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
04 Aug 2026 11:14 AM
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
01 Aug 2026 11:38 AM
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
30 Jul 2026 09:20 AM
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
27 Jul 2026 02:40 PM
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update
Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update
Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update
Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update
Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update
Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update
23 Jul 2026 09:07 AM
Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update
Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.
23 Jul 2026 08:50 AM
Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.
Dr. Reddy's: CLSA on Dr. Reddy's Maintains Hold with Target Price ₹1,240 as gSemaglutide issues and higher freight costs hurt margins, though management expects US growth and margin recovery after November 2026.
23 Jul 2026 08:50 AM
Dr. Reddy's: CLSA on Dr. Reddy's Maintains Hold with Target Price ₹1,240 as gSemaglutide issues and higher freight costs hurt margins, though management expects US growth and margin recovery after November 2026.
Dr. Reddy's: JPMorgan on Dr. Reddy's Maintains Underweight with Target Price ₹1,100 as weak core profitability, higher SG&A and freight costs outweigh recovery hopes from semaglutide and Abatacept launches.
23 Jul 2026 08:50 AM
Dr. Reddy's: JPMorgan on Dr. Reddy's Maintains Underweight with Target Price ₹1,100 as weak core profitability, higher SG&A and freight costs outweigh recovery hopes from semaglutide and Abatacept launches.
Dr. Reddy's: Jefferies on Dr. Reddy's Maintains Underperform with Target Price ₹1,040 as Q1 margins missed sharply on weak US business, higher input costs and semaglutide delays, prompting FY27-29 earnings cuts.
23 Jul 2026 08:50 AM
Dr. Reddy's: Jefferies on Dr. Reddy's Maintains Underperform with Target Price ₹1,040 as Q1 margins missed sharply on weak US business, higher input costs and semaglutide delays, prompting FY27-29 earnings cuts.
Dr Reddy's: Co Executive Reports Higher Freight Costs From Middle East Issues And Increased Solvent Prices Affect EBITDA This Quarter.
22 Jul 2026 05:41 PM
Dr Reddy's: Co Executive Reports Higher Freight Costs From Middle East Issues And Increased Solvent Prices Affect EBITDA This Quarter.
Dr Reddy's: Launches Generic Semaglutide Tablets In India
22 Jul 2026 05:42 PM
Dr Reddy's: Launches Generic Semaglutide Tablets In India
Dr Reddy's: Reports 2.40 Billion Rupee Impact From Semaglutide API In Q1 FY27
22 Jul 2026 04:59 PM
Dr Reddy's: Reports 2.40 Billion Rupee Impact From Semaglutide API In Q1 FY27
Dr. Reddy's: Co. Delays Semaglutide Supply After Some Batches Don't Meet Quality Standards; No Timeline Given For When Supply Will Resume. - Newspaper
10 Jul 2026 09:03 AM
Dr. Reddy's: Co. Delays Semaglutide Supply After Some Batches Don't Meet Quality Standards; No Timeline Given For When Supply Will Resume. - Newspaper
Dr Reddy's Laboratories: Reports Issues With Semaglutide Batches Due To API Problems; Investigating And Delaying Supplies; No Safety Or Regulatory Concerns.
09 Jul 2026 09:19 AM
Dr Reddy's Laboratories: Reports Issues With Semaglutide Batches Due To API Problems; Investigating And Delaying Supplies; No Safety Or Regulatory Concerns.
